BCL2L1 and colorectal carcinoma: Additionally, PKC-ζ inhibition reduced the level of survival proteins, such as BCL-2 by more than 35% (p < 0.02), BCL-XL by more than 45% (p < 0.01), and Survivin by more than 30% in both CRC cells (Figure 9(b,c)).